Last edition
News about "Capvaxive"
Merck, known as MSD outside the United States and Canada, has reported positive results from its Phase 3 STRIDE-13 trial evaluating Capvaxive, its 21-valent pneumococcal conjugate vaccine.
Capvaxive | 12/09/2025 | By Darshana | 230
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members